Stem cells ramping up.., page-56

Hi Pfeifer,

Thanks for responding and my apologies if i didnt formulate my question clearly.

Patent right is very complex and can be confusing i have to admit that. However as far as i  know you can patent the use of X for Y. In our case that would be the use of MSCs for the treatment of aGvHD, CHF, OA ect.

The IP section of MSBs website suggests they did that.

"These patents cover, among other technology areas, a variety of MLCs, including Mesenchymal Precursor Cells (MPCs) and Mesenchymal Stem Cells (MSCs), and the use of MLCs for expansion of hematopoietic stem cells (HSCs). Among the indication-specific issued or pending patents covering product candidates derived from our MLCs are those which provide commercial support for our Tier 1 product candidates - chronic heart failure, chronic low back pain due to disc degeneration, acute graft versus host disease, and chronic inflammation conditions including biologic refractory rheumatoid arthritis, and diabetic nephropathy."

On the IP slide in the last AGM presentation it also showed that they have patented the source including iPSC. 

So if i understand that right, CYP has a patent on their production method for MSCs from iPSCs but the use of the MSCs should still mainly fall into MSBs IP. So that pretty much means that MSB will have exclusive rights for MScs in all the above mentioned indications. Can CYP even commercialise GvHD without breaching one of MSBs patents?

This is a honest question and is not supposed to be a knock on CYP